Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric Yellow Fever 17D/Dengue viruses

Virology

Volumn 429, Issue 2, 2012, Pages 91-98

  Barban, Veronique ^a   Munoz Jordan, Jorge L ^b   Santiago, Gilberto A ^b   Mantel, Nathalie ^a   Girerd, Yves ^a   Gulia, Sandrine ^a   Claude, Jean Baptiste ^a,c   Lang, Jean ^a  

^a SANOFI PASTEUR   (France)

^b Center for Disease Control (CDC)   (Puerto Rico)

^c Genostar   (France)

Author keywords

Breath of protection; Cross neutralization; Dengue epidemiology; Dengue vaccine; Yellow fever dengue chimeric viruses

Indexed keywords

DENGUE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DRUG EFFICACY; DRUG SCREENING; GENOTYPE; HAPLORHINI; IMMUNIZATION; INFECTION PREVENTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; SEROTYPE; VIRUS ISOLATION; VIRUS NEUTRALIZATION; WILD TYPE; YELLOW FEVER;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; DENGUE VACCINES; DENGUE VIRUS; DRUG CARRIERS; GENETIC VECTORS; GENOTYPE; MACACA FASCICULARIS; NEUTRALIZATION TESTS; VACCINES, SYNTHETIC; YELLOW FEVER VIRUS;

DENGUE VIRUS; DENGUE VIRUS GROUP;

EID: 84861666894     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.03.007     Document Type: Article

References (30)

1. Balmaseda A., Standish K., Mercado J.C., Matute J.C., Tellez Y., et al. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J. Infect. Dis. 2010, 201:5-14.
2. Beatty M.E., Beutels P., Meltzer M.I., Shepard D.S., Hombach J., et al. Health economics of dengue: a systematic literature review and expert panel's assessment. Am. J. Trop. Med. Hyg. 2011, 84:473-488.
3. Cassetti M.C., Durbin A., Harris E., Rico-Hesse R., Roehrig J., et al. Report of an NIAID workshop on dengue animal models. Vaccine 2010, 28:4229-4234.
4. Gentry M.K., Henchal E.A., McCown J.M., Brandt W.E., Dalrymple J.M. Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am. J. Trop. Med. Hyg. 1982, 31:548-555.
5. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 2001, 75:7290-7304.
6. Guirakhoo F., Pugachev K., Arroyo J., Miller C., Zhang Z.X., et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 2002, 298:146-159.
7. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 2004, 78:4761-4775.
8. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg. 2009, 80:302-311.
9. Guy B., Saville M., Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum. Vaccine 2010, 6:696-705.
10. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., et al. Dengue: a continuing global threat. Nat. Rev. Microbiol. 2010, 8:S7-16.
11. Halstead S.B., Simasthien P. Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host. Yale J. Biol. Med. 1970, 42:276-292.
12. Halstead S.B., Shotwell H., Casals J. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J. Infect. Dis. 1973, 128:7-14.
13. Holmes E.C., Twiddy S.S. The origin, emergence and evolutionary genetics of dengue virus. Infect. Genet. Evol. 2003, 3:19-28.
14. Kärber G. Beitrag zur kollektiven Behandlung pharmakologisher Reihenversuche. Arch. Exp. Pathol. Pharmakol. 1931, 162:480-483.
15. Klungthong C., Putnak R., Mammen M.P., Li T., Zhang C. Molecular genotyping of dengue viruses by phylogenetic analysis of the sequences of individual genes. J. Virol. Methods 2003, 154:175-181.
16. Kochel T.J., Watts D.M., Halstead S.B., Hayes C.G., Espinoza A., et al. Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever. Lancet 2002, 360:310-312.
17. Kouri G.P., Guzman M.G., Bravo J.R., Triana C. Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull. World Health Organ. 1989, 67:375-380.
18. Lewis J.A., Chang G.J., Lanciotti R.S., Kinney R.M., Mayer L.W., et al. Phylogenetic relationships of dengue-2 viruses. Virology 1993, 197:216-224.
19. Rico-Hesse R., Harrison L.M., Salas R.A., Tovar D., Nisalak A., et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 1997, 230:244-251.
20. Rico-Hesse R. Microevolution and virulence of dengue viruses. Adv. Virus Res. 2003, 59:315-341.
21. Rodrigo W.W., Alcena D.C., Kou Z., Kochel T.J., Porter K.R., et al. Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2. Clin. Vaccine Immunol. 2009, 16:285-287.
22. Roehrig J.T., Hombach J., Barrett A.D. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 2008, 21:123-132.
23. Russell P.K., McCown J.M. Comparison of dengue-2 and dengue-3 virus strains by neutralization tests and identification of a subtype of dengue-3. Am. J. Trop. Med. Hyg. 1972, 21:97-99.
24. Simmons J.S., John J.H., Reynolds F.H.K. Experimental studies of dengue. Philipp. J. Sci. 1931, 44:1-251.
25. Steel A., Gubler D.J., Bennett S.N. Natural attenuation of dengue virus type-2 after a series of island outbreaks: a retrospective phylogenetic study of events in the South Pacific three decades ago. Virology 2010, 405:505-512.
26. Tajima S., Nukui Y., Takasaki T., Kurane I. Characterization of the variable region in the 3' non-translated region of dengue type 1 virus. J. Gen. Virol. 2007, 88:2214-2222.
27. Vu T.T., Holmes E.C., Duong V., Nguyen T.Q., Tran T.H., et al. Emergence of the Asian 1 genotype of dengue virus serotype 2 in viet nam: in vivo fitness advantage and lineage replacement in South-East Asia. PLoS Negl. Trop. Dis. 2010, 4:757-764.
28. Wang E., Ni H., Xu R., Barrett A.D., Watowich S.J., et al. Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J. Virol. 2000, 74:3227-3234.
29. Whitehead S.S., Blaney J.E., Durbin A.P., Murphy B.R. Prospects for a dengue virus vaccine. Nat. Rev. Microbiol. 2007, 5:518-528.
30. Zhang C., Mammen M.P., Chinnawirotpisan P., Klungthong C., Rodpradit P., et al. Clade replacements in dengue virus serotypes 1 and 3 are associated with changing serotype prevalence. J. Virol. 2005, 79:15123-15130.